Axa S.A. Takes $1.66 Million Position in LivaNova PLC (NASDAQ:LIVN)

AXA S.A. purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 35,892 shares of the company's stock, valued at approximately $1,662,000. AXA S.A. owned about 0.07% of LivaNova as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. grew its position in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after purchasing an additional 1,441 shares during the period. Vestcor Inc acquired a new stake in LivaNova in the fourth quarter worth about $204,000. Optimize Financial Inc acquired a new stake in LivaNova in the fourth quarter worth about $208,000. Finally, Inceptionr LLC purchased a new stake in shares of LivaNova in the fourth quarter worth approximately $217,000. Institutional investors own 97.64% of the company's stock.

LivaNova Trading Down 2.6%

NASDAQ:LIVN traded down $1.17 on Tuesday, hitting $44.06. 931,463 shares of the stock were exchanged, compared to its average volume of 641,544. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 104.90 and a beta of 0.84. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $63.57. The company's 50-day moving average price is $37.98 and its 200 day moving average price is $45.04. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Analysts Set New Price Targets

A number of analysts have recently issued reports on LIVN shares. StockNews.com lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and set a $64.00 price target on shares of LivaNova in a report on Tuesday. Barclays lowered their price target on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Wolfe Research cut shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Finally, Robert W. Baird lifted their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $59.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.